Elicit · Adoption
Elicit Reaches 5M+ Researchers Across Pharma, Academia, and Policy
What looked like a niche academic tool has spread into pharma R&D and policy research institutions, taking on the shape of an emerging industry standard.
From Niche to Emerging Standard
A year ago Elicit read as a niche academic curiosity — pharma and policy applications were still exceptions.
5M+ researchers use it; adopted by pharma R&D teams, universities, and policy think tanks worldwide. The shift from academic niche to cross-industry platform is now confirmed in the user numbers.
Who's Using It
Early adopters
Pharma R&D teams for clinical evidence collection, universities for systematic literature reviews, policy think tanks for evidence report production.
Still difficult
Individual researchers and undergraduates for casual use. The feature depth is high, and setup friction is a real barrier for one-off searches.
Don't Lose the Early-Adopter Window
Organizations adopting early will have a workflow edge. Starting now means tool proficiency and internal workflow development grow in parallel, widening the gap against competitors who wait.
Solo research use cases remain complex to set up. Team- or institution-level adoption is the realistic entry point.